Before any strategy can be formulated for next year’s appropriations, cancer groups must confront the formidable challenge of figuring out how much of President Joe Biden’s vision for cancer research is realistic.
NCI-designated cancer centers and academic medical institutions (AMCs) are facing unprecedented threats that jeopardize their ability to conduct groundbreaking research, deliver cutting-edge care, and sustain clinical trials essential to patient treatment.
